DOLEŽALOVÁ, Lenka, Lucie BLÁHOVÁ, Jan KUTA, Tereza HOJDAROVÁ, Šárka KOZÁKOVÁ and Luděk BLÁHA. Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies (Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies. Environmental Science and Pollution Research). Environmental Science and Pollution Research. Heidelberg: Springer Heidelberg, 2022, vol. 29, No 18, p. 26810-26819. ISSN 0944-1344. Available from: https://dx.doi.org/10.1007/s11356-021-17607-y.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies
Authors DOLEŽALOVÁ, Lenka (203 Czech Republic, belonging to the institution), Lucie BLÁHOVÁ (203 Czech Republic, belonging to the institution), Jan KUTA (203 Czech Republic, belonging to the institution), Tereza HOJDAROVÁ (203 Czech Republic, belonging to the institution), Šárka KOZÁKOVÁ (203 Czech Republic) and Luděk BLÁHA (203 Czech Republic, guarantor, belonging to the institution).
Edition Environmental Science and Pollution Research, Heidelberg, Springer Heidelberg, 2022, 0944-1344.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.800
RIV identification code RIV/00216224:14310/22:00125197
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1007/s11356-021-17607-y
UT WoS 000725470500032
Keywords in English Surface contamination; Occupational exposure; Antineoplastic drugs; Hospital pharmacy; 5-fluorouracil; Cyclophosphamide; Platinum derivatives; Gemcitabine
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 4/4/2023 09:49.
Abstract
The consumption of hazardous antineoplastic drugs (ADs) used in anticancer chemotherapies is steadily increasing representing thus risks to both human health and the environment. Hospitals may serve as a contamination source, and pharmacists preparing the antineoplastic drugs (ADs) as well as nurses administering chemotherapy and caring for oncology patients are among the healthcare professionals being highly exposed. Here, we present the results of systematic monitoring (2018-2020) of surface contamination by 13 ADs in the pharmacies and hospitals in the Czech Republic (CZ; large-scale monitoring, 20 workplaces) and Slovak Republic (SK; pilot study at 4 workplaces). The study evaluated contamination by three commonly monitored ADs, i.e., 5-fluorouracil (FU), cyclophosphamide (CP), and platinum (total Pt representing cis-, carbo-, and oxaliplatin) together with ten less explored ADs, i.e., gemcitabine (GEM), ifosfamide (IF), paclitaxel (PX), irinotecan (IRI), docetaxel (DOC), methotrexate (MET), etoposide (ETOP), capecitabine (CAP), imatinib (IMAT), and doxorubicin (DOX). Floors and desktop surfaces in hospitals (chemotherapy application rooms, nurse working areas) were found to be more contaminated, namely with CP and Pt, in both countries when compared to pharmacies. Comparison between the countries showed that hospital surfaces in SK are generally more contaminated (e.g., CP median was 20 times higher in SK), while some pharmacy areas in the CZ were more contamined in comparison with SK. The newly studied ADs were detected at lower concentrations in comparison to FU, CP, and Pt, but some markers (GEM, IF, PX, and IRI) were frequently observed, and adding these compounds to routine monitoring is recommended.
Links
EF17_043/0009632, research and development projectName: CETOCOEN Excellence
LM2018121, research and development projectName: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI
NV18-09-00188, research and development projectName: Monitoring expozice cytotoxickým léčivům u pracovníků ve zdravotnictví a rodinných příslušníků onkologických pacientů, analýza rizik, zpracování doporučených postupů
Investor: Ministry of Health of the CR
PrintDisplayed: 6/9/2024 12:34